Stefan Merz
CIK 1583175 · View on SEC EDGAR ↗
First SEC filing: Aug. 3, 2016 · Latest: Aug. 3, 2016
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Aug. 1, 2016 | DBD | F | 1,880 | $27.45 | $51,606 | 22,627 Direct | -7.67% | Disposed | 145.5% (price as of 2026-08-20) |
| Feb. 11, 2016 | DBD | A | 10,000 | $23.01 | $230,100 | 24,507 Direct | +68.93% | Acquired | 192.9% (price as of 2026-08-20) |
| Feb. 3, 2016 | DBD | A | 22,346 | $27.39 | $612,057 | 22,346 Direct | — | Acquired | 146.0% (price as of 2026-08-20) |
| Feb. 3, 2016 | DBD | A | 3,038 | $27.39 | $83,211 | 14,507 Direct | +26.49% | Acquired | 146.0% (price as of 2026-08-20) |
| Feb. 12, 2015 | DBD | F | 1,186 | $34.75 | $41,214 | 11,469 Direct | -9.37% | Disposed | 93.9% (price as of 2026-08-20) |
| Feb. 12, 2015 | DBD | A | 3,072 | $34.75 | $106,752 | 12,655 Direct | +32.06% | Acquired | 93.9% (price as of 2026-08-20) |
| Feb. 5, 2015 | DBD | A | 20,060 | $32.33 | $648,540 | 20,060 Direct | — | Acquired | 108.4% (price as of 2026-08-20) |
| Feb. 5, 2015 | DBD | A | 2,361 | $32.33 | $76,331 | 9,583 Direct | +32.69% | Acquired | 108.4% (price as of 2026-08-20) |
| Feb. 12, 2014 | DBD | A | 14,750 | $34.13 | $503,418 | 14,750 Direct | — | Acquired | 97.5% (price as of 2026-08-20) |
| Feb. 12, 2014 | DBD | A | 1,922 | — | — | 7,222 Direct | +36.26% | Acquired | (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 3, 2016 | DBD | Non-Qualified Stock Option [F3] | Common Shares (22,346) | $27.39 | Feb. 3, 2026 | 22,346 | Acquired |
| Feb. 5, 2015 | DBD | Non-Qualified Stock Option [F3] | Common Shares (20,060) | $32.33 | Feb. 5, 2025 | 20,060 | Acquired |
| Feb. 12, 2014 | DBD | Non-Qualified Stock Option [F3] | Common Stock (14,750) | $34.13 | Feb. 12, 2024 | 14,750 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
DBD
President, Corporate Strategy and Development| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2016 | — | — | — | — | $295,200 | — | $61,774 | $1,387,364 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.